In 2026, the Medicare Part D out-of-pocket cap rises to $2,100, up from $2,000 in 2025. The cap was created by the Inflation Reduction Act of 2022 and represents the most significant structural change to the Part D benefit since its creation in 2003. Once a beneficiary's deductible, copayments, and coinsurance for covered Part D drugs reach $2,100 in a calendar year, the plan covers 100% of covered drug costs for the remainder of the year.
For manufacturer access teams, the cap is not just a patient-affordability fact. It reshapes how copay assistance programs function, how hub services screen patients for financial support, when patient assistance programs should be deployed, and how commercial teams message affordability to providers and prescribers.
This article is for manufacturer market access directors, hub services operators, patient support program managers, specialty pharmacy liaisons, and payer strategy teams who need to integrate the $2,100 cap into their affordability workflows and field reimbursement guidance.
The 2026 Part D benefit structure in three phases
The 2025 Part D redesign eliminated the coverage gap (donut hole) entirely and created a three-phase structure that continues in 2026 with adjusted thresholds:
| Phase | What the beneficiary pays | When it applies |
|---|---|---|
| Deductible | 100% of drug costs | Up to $615 maximum (plan year 2026); some plans have lower or $0 deductible |
| Initial coverage | Copay or coinsurance (varies by drug tier) | After deductible until true out-of-pocket (TrOOP) reaches $2,100 |
| Catastrophic coverage | $0 for covered drugs | After TrOOP reaches $2,100 through end of calendar year |
The $2,100 cap is automatic. Beneficiaries do not need to enroll or apply. Plans track out-of-pocket spending and transition the beneficiary to catastrophic coverage when the threshold is reached.
What counts toward the $2,100 cap
The following amounts count toward the out-of-pocket maximum:
- The beneficiary's deductible payments
- Copayments and coinsurance for covered Part D drugs
- Amounts paid by the beneficiary, by family members, or by most third parties on behalf of the beneficiary
- The manufacturer discount under the IRA Manufacturer Discount Program during the initial coverage phase
What does not count toward the cap
- Monthly Part D plan premiums
- Costs for drugs not covered under the Part D plan (including Part B drugs, over-the-counter drugs, and drugs excluded from the plan's formulary)
- Costs for drugs received through the Medicare GLP-1 Bridge demonstration, which operates outside Part D
- Costs for non-Part D benefits
The PAN Foundation and CMS have both confirmed these parameters in their 2026 guidance materials.
How the cap changes manufacturer affordability strategy
The problem with copay assistance under the cap
Before the IRA, manufacturer copay assistance for Part D drugs was structurally straightforward: the copay card reduced the patient's out-of-pocket cost, and the remaining coinsurance or copayment counted toward the catastrophic threshold. Once the patient reached catastrophic coverage (previously with 5% coinsurance, now $0), the plan paid the rest.
The $2,100 cap changes the economics in two ways:
The cap is low enough that many specialty drug patients reach it quickly. A patient on a $10,000-per-month specialty drug with 25% coinsurance hits $2,100 in out-of-pocket costs in less than one fill cycle. After that, the patient pays $0 for the rest of the year.
Manufacturer copay assistance accelerates the path to $0, but does not change the ceiling. If a manufacturer provides a $12,000 annual copay card, the card pays the patient's cost share until the $2,100 cap is reached (typically within the first few fills), and then the plan pays everything. The manufacturer's copay assistance is consumed in the first quarter of the year, and the patient is protected by the cap for the remaining nine months.
This dynamic means manufacturer copay assistance for Part D patients has diminishing marginal utility. Once the patient reaches the cap, the copay card is irrelevant. The manufacturer's support budget is spent early, and the plan absorbs all remaining costs.
Implications for hub screening
Hub services teams screening Medicare patients for affordability options should adjust their workflows:
| Old workflow | Adjusted workflow for 2026 |
|---|---|
| Determine if patient has Part D coverage | Same |
| Estimate patient's annual out-of-pocket cost under plan's tier structure | Calculate how quickly the patient will reach $2,100 based on drug cost and coinsurance |
| Determine if copay assistance is needed for the full year | Recognize that copay assistance is only needed until the cap is reached |
| Enroll patient in copay card program for full year | Enroll patient in copay card but flag expected cap date; plan for program exit mid-year |
| Assess patient for PAP if copay card is insufficient | PAP is rarely needed for Part D patients who will reach catastrophic coverage quickly |
A ZS analysis published in 2025 described the cap's effect on pharma affordability strategy: "Without the MPPP, the $2,000 cap on patient spending could still be an insurmountable expense for a large portion of patients who are asked to pay significant cost sharing, if not the full amount, on their first script of a branded medicine." The 2026 increase to $2,100 is marginal, but the structural insight remains valid — the cap creates a predictable ceiling, and manufacturer support should be designed around reaching it efficiently.
The Medicare Prescription Payment Plan
The Medicare Prescription Payment Plan (MPPP), also created by the IRA, allows beneficiaries to spread their out-of-pocket costs evenly across the calendar year instead of paying large sums at the pharmacy counter early in the year. Under the MPPP:
- The beneficiary pays $0 at the point of sale for each prescription
- The plan bills the beneficiary monthly for their share of costs, smoothed across 12 months
- The beneficiary never pays more than their total out-of-pocket obligation (maximum $2,100 in 2026)
- Once the cap is reached, the monthly payment drops to $0
CMS's official MPPP fact sheet provides an example where a beneficiary with a $525 monthly drug cost makes monthly payments of approximately $190 instead of paying $525 upfront in January and February.
For manufacturer hub teams, the MPPP matters because it reduces the urgency of copay assistance for Part D patients. A patient who opts into the MPPP can manage their cash flow without manufacturer support, though their total annual out-of-pocket cost is the same $2,100. The MPPP is a cash-flow tool, not a discount.
When manufacturer support still matters
Despite the cap, manufacturer assistance programs remain relevant in specific scenarios:
The drug is not on the plan's formulary or is on a non-preferred tier with high coinsurance. The cap protects the patient eventually, but the path to $2,100 may require copay assistance in the first quarter.
The patient needs bridge support before the PA is approved. Manufacturer bridge programs that provide free drug during the PA process are not affected by the cap, because the patient is not yet filling through Part D.
The patient is near the end of the calendar year and has not yet reached the cap. If a patient starts therapy in November and has only one or two months to accumulate toward $2,100, copay assistance may still be needed for the current year.
The patient has a Part D plan with a deductible. The 2026 maximum deductible is $615. Patients who have not yet met the deductible face 100% of drug costs until they do. Copay assistance can bridge this gap.
The patient takes multiple specialty drugs. A patient on two or three specialty drugs may reach the cap faster, but the coinsurance burden before reaching the cap may be significant.
How the Manufacturer Discount Program interacts with the cap
The IRA replaced the Coverage Gap Discount Program with the Manufacturer Discount Program starting in 2025. Under the new program, manufacturers must provide a discount on Part D drugs during the initial coverage phase. The discount counts toward the beneficiary's out-of-pocket costs, meaning it accelerates the patient's path to the $2,100 cap.
CMS finalized the Manufacturer Discount Program guidance and continues to update participation instructions. For 2026 and subsequent years, manufacturer agreements become effective on the first day of a calendar quarter that is at least 60 days after signing. CMS began issuing new Part D "P" numbers on August 1, 2025.
The manufacturer discount is mandatory for participating manufacturers (which includes virtually all manufacturers with Part D-covered drugs). It is not a voluntary support program. The discount rate is defined by statute and phased in over several years.
Key implication for access teams
The mandatory manufacturer discount means that the patient's out-of-pocket costs are partially offset by the manufacturer's statutory obligation. Copay assistance programs should be layered on top of — not duplicative of — the mandatory discount. Hub screening workflows should confirm that the patient is receiving the statutory discount before enrolling them in copay assistance.
Affordability messaging changes for the field
Manufacturer field reimbursement managers and access liaisons should update their provider-facing messaging for the 2026 plan year:
Lead with the cap, not the copay card. Providers should understand that most Medicare patients will reach $2,100 in out-of-pocket costs early in the year and then pay $0. The copay card bridges the gap to the cap but does not provide additional value beyond it.
Screen for MPPP eligibility. Before recommending copay assistance, determine whether the patient has opted into the MPPP. If yes, the patient's monthly costs are already smoothed, and copay assistance may not be necessary.
Differentiate Part D from Part B and Bridge program costs. The $2,100 cap does not apply to Part B drugs (injectable and infused biologics administered in clinical settings) or to the GLP-1 Bridge demonstration. Patients on multiple benefit types may have separate cost obligations.
Account for the January reset. Every January 1, the out-of-pocket accumulator resets to $0. Patients who were in catastrophic coverage in December face full cost-sharing again in January. This is the highest-risk month for treatment abandonment and the most important month for copay assistance.
Factor in the deductible. The 2026 maximum deductible is $615, up from $590 in 2025. For patients on high-cost specialty drugs, the deductible is typically met with the first fill, but copay assistance may be needed to cover it.
How to build the 2026 hub screening workflow
A revised hub screening process for Medicare Part D patients should include these steps:
- Confirm the patient has active Part D coverage (standalone PDP or Medicare Advantage with drug coverage)
- Identify whether the drug is on the plan's formulary and at which tier
- Determine the patient's coinsurance or copayment for the drug's tier
- Calculate the number of fills needed to reach the $2,100 cap
- Check if the patient is enrolled in the MPPP
- Check if the patient qualifies for Extra Help (LIS), which provides additional cost protection
- Determine whether copay assistance is needed (typically only for the first quarter of the year)
- If the patient does not qualify for LIS and has not opted into MPPP, assess whether the copay card provides sufficient protection until the cap is reached
- If the drug is not on formulary, initiate prior authorization or formulary exception
What to monitor next
Annual cap adjustment: The $2,100 cap is indexed to drug spending growth. CMS will announce the 2027 cap in late 2026. Manufacturer hub workflows should be designed to accommodate annual changes without reprogramming.
IRA negotiated drug prices: The first round of IRA-negotiated prices took effect January 1, 2026. Negotiated prices reduce the plan's cost but do not change the $2,100 cap. However, lower negotiated prices may cause plans to adjust tier placement and coinsurance rates, which changes how quickly patients reach the cap.
MPPP adoption rates: Early data on MPPP opt-in rates will determine how many Part D patients are using the smoothing program and how many still need copay assistance for cash-flow management.
Manufacturer Discount Program compliance: CMS is monitoring manufacturer participation and discount calculations. Non-compliance could affect a manufacturer's Part D coverage.
This article provides general information about the Medicare Part D out-of-pocket cap and its implications for manufacturer access strategy. It does not constitute reimbursement advice for any specific patient or plan. Coverage policies, formulary placement, and cost-sharing structures vary by plan and product. Always verify current plan benefits before providing affordability guidance.
Sources
- PAN Foundation. "Understanding the Medicare Part D Cap." Updated 2026. https://www.panfoundation.org/understanding-the-medicare-part-d-cap
- PAN Foundation. "Everything You Need to Know About Medicare Reforms." Updated October 2025. https://www.panfoundation.org/everything-you-need-to-know-about-medicare-reforms
- UnitedHealthcare. "How Medicare Part D Is Changing in 2026." https://www.uhc.com/medicare/medicare-education/part-d-changes.html
- CMS. "Part D Information for Pharmaceutical Manufacturers." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/part-d-information-pharmaceutical-manufacturers
- CMS. "Medicare Part D Improvements." https://www.cms.gov/priorities/medicare-prescription-drug-affordability/overview/medicare-part-d-improvements
- CMS. "What's the Medicare Prescription Payment Plan?" (Fact Sheet, Publication 12211). https://www.medicare.gov/publications/12211-whats-the-medicare-prescription-payment-plan.pdf
- AARP. "3 Prescription Drug Changes Coming to Medicare in 2026." https://www.aarp.org/medicare/future-medicare-drug-payment-changes-2026
- ZS. "Medicare Part D Reform: Pharma's Impact and Opportunities in IRA." https://www.zs.com/insights/ira-medicare-part-d-changes-mppp-how-pharma-can-prepare
- NCOA. "Who Pays What for Medicare Part D in 2026: A Guide." https://www.ncoa.org/article/who-pays-what-for-medicare-part-d-in-2026-a-guide
- Boomer Benefits. "How the Medicare Part D $2,100 Cap Works in 2026." https://boomerbenefits.com/how-the-medicare-part-d-2100-cap-works-in-2026
